Commentary | Published:

Making individualized drugs a reality

Nature Biotechnology volume 35, pages 507513 (2017) | Download Citation

  • An Erratum to this article was published on 08 August 2017

This article has been updated

Magistral drug preparation offers a model to circumvent many of the technological, regulatory and financial challenges that prevent provision of the right drug at the right time to the right patient.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Change history

  • 05 June 2017

    In the version of this article initially published, the line “Editor’s note: This article has been peer-reviewed.” was omitted. The error has been corrected in the HTML and PDF versions of the article.

References

  1. 1.

    & Health Aff. (Millwood) 32, 1116–1125 (2013).

  2. 2.

    et al. Lancet Oncol. 16, 1324–1334 (2015).

  3. 3.

    et al. Br. Med. J. 329, 15–19 (2004).

  4. 4.

    & N. Engl. J. Med. 372, 2229–2234 (2015).

  5. 5.

    et al. Value Health 15, 1162–1171 (2012).

  6. 6.

    & Maturitas 82, 94–99 (2015).

  7. 7.

    Nat. Biotechnol. 29, 751–756 (2012).

  8. 8.

    & Nature 467, 543–549 (2010).

  9. 9.

    Int. J. Clin. Pharm. 37, 669–670 (2015).

  10. 10.

    & N. Engl. J. Med. 372, 793–795 (2015).

  11. 11.

    N. Engl. J. Med. 361, 737–740 (2009).

  12. 12.

    N. Engl. J. Med. 367, 193–197 (2012).

  13. 13.

    Value Health 16 Suppl, S27–S31 (2013).

  14. 14.

    Urol. Oncol. 32, 202–206 (2014).

  15. 15.

    Metabolism 62 Suppl 1, S1–14 (2013).

  16. 16.

    , & Drug Discov. Today 19, 1711–1720 (2014).

  17. 17.

    European Public Assessment Report Glybera (EMA Website)

  18. 18.

    Ann. NY Acad. Sci. 1346, 81–89 (2015).

  19. 19.

    et al. Clin. Cancer Res. 20, 1081–1086 (2014).

  20. 20.

    et al. J. Biomol. Screen. 20, 545–551 (2015).

  21. 21.

    et al. J. Am. Chem. Soc. 127, 11228–11229 (2005).

  22. 22.

    N. Engl. J. Med. 351, 1707–1709 (2004).

  23. 23.

    , , & Health Policy 117, 328–333 (2014).

  24. 24.

    , , & J. Manag. Care Spec. Pharm. 20, 1183–1191 (2014).

  25. 25.

    et al. Transfusion 48, 1754–1762 (2008).

  26. 26.

    , , & Expert Opin. Drug Saf. 11, 797–801 (2012).

  27. 27.

    et al. MAbs 5, 810–816 (2013).

  28. 28.

    & Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 50, 1213–1220 (2007).

  29. 29.

    & Dev. Biol. 112, 81–97 (2003).

  30. 30.

    , , , & Br. Med. J. 352, i788 (2016).

  31. 31.

    et al. Nanoscale 6, 6293–6300 (2014).

  32. 32.

    , & Org. Biomol. Chem. 10, 2713–2729 (2012).

  33. 33.

    et al. Angew. Chem. Int. Edn Engl. 55, 5904–5937 (2016).

Download references

Author information

Affiliations

  1. Huub Schellekens, Herre Talsma & Enrico Mastrobattista are in the Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, The Netherlands

    • Huub Schellekens
    • , Herre Talsma
    •  & Enrico Mastrobattista
  2. Mohammed Aldosari is in the Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, The Netherlands, and the Saudi Food and Drug Administration, Riyadh, Saudi Arabia

    • Mohammed Aldosari

Authors

  1. Search for Huub Schellekens in:

  2. Search for Mohammed Aldosari in:

  3. Search for Herre Talsma in:

  4. Search for Enrico Mastrobattista in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Huub Schellekens.

Supplementary information

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt.3888

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing